5-溴-2-氯-4-甲基-3-硝基吡啶 | 884495-15-2

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 5-溴-2-氯-4-甲基-3-硝基吡啶
• 中文别名: 2-氯-3-硝基-4-甲基-5-溴吡啶
• 英文名称: 5-bromo-2-chloro-4-methyl-3-nitropyridine
• 英文别名: 2-chloro-3-nitro-5-bromo-4-picoline
• CAS: 884495-15-2
• 化学式: C₆H₄BrClN₂O₂
• 分子量: 251.467
• InChiKey: BLJOCKNDWUTFEN-UHFFFAOYSA-N

物化性质

• 沸点：
  304.4±37.0 °C(Predicted)
• 密度：
  1.810±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-2-chloro-4-methyl-3-nitropyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-2-chloro-4-methyl-3-nitropyridine
CAS number: 884495-15-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H4BrClN2O2
Molecular weight: 251.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-2-氯-4-甲基-3-硝基吡啶 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 硼烷四氢呋喃络合物 、 potassium acetate 、 potassium carbonate 、 溶剂黄146 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 lithium hexamethyldisilazane 、 锌 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 14.0h， 生成 tert-butyl 7-(5-((2,4-dimethoxybenzyl)amino)-2-((1-ethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)-8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate
  参考文献：
  名称：

  开发一系列喹唑啉-2,5-二胺衍生物作为强效造血祖细胞激酶 1 (HPK1) 抑制剂

  摘要：

  造血祖细胞激酶 1 (HPK1) 是一种丝氨酸/苏氨酸激酶，可作为多种免疫信号通路的负调节因子。使用 HPK1 敲除小鼠和激酶死亡小鼠的遗传研究表明，单独抑制 HPK1 或与免疫检查点阻断联合抑制 HPK1 可能是癌症免疫治疗中有前途的策略。在此，我们报告了一系列带有喹唑啉-2,5-二胺支架的强效 HPK1 抑制剂的设计、合成和构效关系 (SAR) 研究。三轮 SAR 探索导致9h的鉴定，这是该系列中最有效的化合物，它具有 2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl 取代基。使用人类免疫细胞的进一步生物学评估表明，9h可以强烈抑制下游磷酸化，增加白细胞介素 2 (IL-2) 的产生和逆转前列腺素 E2 (PGE2) 诱导的免疫抑制。总的来说，我们对这些喹唑啉-2,5-二胺衍生物的研究不仅为社区提供了一种工具化合物来帮助阐明 HPK1 药理学，而且为后续开发

  DOI：

  10.1016/j.ejmech.2022.115064
• 作为产物：
  描述：

  2-氨基-5-溴-3-硝基-4-甲基吡啶 在 盐酸 、 sodium nitrite 作用下， 以 水 为溶剂， 以60 %的产率得到5-溴-2-氯-4-甲基-3-硝基吡啶
  参考文献：
  名称：

  [EN] TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS
  [FR] DÉRIVÉS TRICYCLIQUES UTILES EN TANT QU'INHIBITEURS DE PARP7

  摘要：

  公开号：

  WO2022170974A9

文献信息

• [EN] SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE<br/>[FR] INHIBITEURS À PETITE MOLÉCULE DE KINASE INDUISANT NF-KB
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020239999A1

  公开（公告）日：2020-12-03

  The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

  本发明涉及抑制NIK的化合物，以及包含这些化合物的药物组合物和使用方法。这些化合物和药物组合物预期能用于预防或治疗癌症（如包括白血病、淋巴瘤和多发性骨髓瘤的B细胞恶性肿瘤）、炎症性疾病、自身免疫疾病、免疫皮肤病学疾病（如掌跖脓疱病和化脓性汗腺炎）以及代谢紊乱疾病（如肥胖和糖尿病）。
• [EN] IDO INHIBITORS<br/>[FR] INHIBITEURS DE L'IDO
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015002918A1

  公开（公告）日：2015-01-08

  There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

  公开了化合物(I)的结构，该化合物调节或抑制色氨酸2,3-二氧化酶(IDO)的酶活性，包含该化合物的药物组合物以及利用该发明的化合物治疗增殖性疾病，如癌症、病毒感染和/或炎症性疾病的方法。
• PDE4 INHIBITOR
  申请人：SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD.

  公开号：US20190177318A1

  公开（公告）日：2019-06-13

  Provided are a PDE4 inhibitor and a use thereof in the preparation of a medicament for treating PDE4 related diseases. Specifically disclosed are the compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.

  提供了一种PDE4抑制剂及其在制备用于治疗与PDE4相关疾病的药物中的用途。具体披露了如公式（I）所示的化合物及其药用可接受的盐。
• Preparation of the HIV Attachment Inhibitor BMS-663068. Part 1. Evolution of Enabling Strategies
  作者：Richard J. Fox、Jonathan C. Tripp、Mitchell J. Schultz、Joseph F. Payack、Dayne D. Fanfair、Boguslaw M. Mudryk、Saravanababu Murugesan、Chung-Pin H. Chen、Thomas E. La Cruz、Sabrina E. Ivy、Sévrine Broxer、Ryan Cullen、Deniz Erdemir、Peng Geng、Zhongmin Xu、Alan Fritz、Wendel W. Doubleday、David A. Conlon

  DOI：10.1021/acs.oprd.7b00134

  日期：2017.8.18

  installation route was developed which involved the conversion of a late-stage common intermediate to an N(1)-thioether derivative followed by chloromethylation, displacement with di-t-butylpotassium phosphate, and deprotection. This second strategy resulted in the multikilogram scale preparation of the API in 14 linear steps and ∼7% overall yield.

  描述了开发两个导致生产> 1000 kg BMS-663068（3）的可行途径的过程。为支持发展活动和最初的临床试验而确定的最初100千克递送的路线涉及将2-氨基-4-甲基吡啶转化为母体活性药物成分（API），然后进行前药安装和脱保护。为了消除二的父API和合成的问题的隔离吨丁基（氯甲基）酯，磷酸一第二代前药安装路线被开发其中涉及一个后期常用中间体的转化为N（1） -thioether衍生物随后氯甲基，位移二吨丁基磷酸钾，并脱保护。第二种策略导致API以14线性步长的多千克级规模制备API，总产率约为7％。
• ISOQUINOLINES AS INHIBITORS OF HPK1
  申请人：Genentech, Inc.

  公开号：US20180282282A1

  公开（公告）日：2018-10-04

  Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

  描述了异喹啉化合物及其作为HPK1（造血激酶1）抑制剂的用途。这些化合物在治疗依赖于HPK1的疾病和增强免疫应答方面非常有用。还描述了抑制HPK1的方法、治疗依赖于HPK1的疾病的方法、增强免疫应答的方法，以及制备异喹啉化合物的方法。